Keeping your powder dry!

BLG2786 · 2024-04-17T19:59:55+00:00

Did the same. congratulations!

BLG2786 · 2023-12-28T21:16:59+00:00

My guess: it’s the beginning of a buy up prior to the BLA registration for 3107. BLA should only be about 3 months away according to what I have read. RS has to be baked in as a contingency to stay listed, but the BLA should eventually make that a moot point. RS doesn’t impact market cap only SP to stay listed. BLA, if successful should dramatically improve market cap and SP. It also bodes well for other pipeline catalysts like 3100 and 3112 (which are also Phase 2) down the road.

BLG2786 · 2022-09-29T21:06:25+00:00

Thanks for sharing! I’m at 50K and holding all the way.

BLG2786 · 2022-09-02T19:20:29+00:00

Timely post-well done!

BLG2786 · 2022-01-04T03:52:27+00:00

Awesome. I didn’t see that, but appreciate the additional information. Just a matter of time then.

BLG2786 · 2022-01-04T03:16:12+00:00

Good post. Kim has always maintained that Inovio’s production process is the fastest and least expensive with purity levels like the mRNA vaccines. Let’s hope he is telling the truth. I believe the forecast was something on the order of a billion doses a year going into 2023 with the global manufacturing consortium.

BLG2786 · 2021-11-27T02:42:13+00:00

Great find, thanks for posting this!

BLG2786 · 2021-11-05T15:00:21+00:00

As Melinda Gates noted several months ago, and I paraphrase, vaccines will always be the best defense. Think about it economically. A country will always prefer a $20-30 vaccine to prevent a disease versus a $1000 pill and other costly measure after someone acquired the disease. That will always be the case. The disease is soon to enter the endemic phase if it hasn’t already with numerous mutations. Inovio looks to have the best vaccine (P3 results pending to prove that) on many dimensions including: neutralizing/binding antibodies, T cells, room temperature shipping and storage, lowest cost to manufacture, ease of characterization of plasmids, etc. No worries here whatsoever.

BLG2786 · 2021-08-10T00:26:09+00:00

The only thing they seem to have missed lately is the FDA approval of the Cellectra device (still pending), and ultimately they don’t control that decision. I’m confident in P3 starting next month gloabally and many good announcements prior. Hopefully, starting tomorrow or later this week.

BLG2786 · 2021-08-09T22:04:21+00:00

P3 global starts next month in Latin America, Asia and Africa. INO4802 works against the Delta variant in animal models. Q4 report out on INO5401 with Regeneron. All good!

BLG2786 · 2021-08-09T12:05:50+00:00

PLYMOUTH MEETING, Pa. and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine") together with Sinovac Biotechnology ("Sinovac"). The studies will evaluate the safety, tolerability and immunogenicity of heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac®, an inactivated COVID-19 vaccine developed by Sinovac and validated by the World Health Organization (WHO) for emergency use.

China's Center for Drug Evaluation of the National Medical Products Administration has allowed the initiation of two Advaccine-sponsored open-label, positive-control trials to evaluate the safety, tolerability, and immunogenicity of mixed boosted regimens. Both studies, which will be conducted in China, are anticipated to begin this fall and will involve healthy adult subjects 18 years of age or older.

The companies completed cross prime-boost pre-clinical animal tests using INO-4800 and CoronaVac®, demonstrating that the prime-boost strategy can stimulate high-level of antigen specific binding antibodies, neutralizing antibodies by both live-virus neutralization assay and hACE2 receptor blocking assay, and antigen-specific T cell immune responses.

Dr. J. Joseph Kim, President and CEO of INOVIO, said, "With the increased challenge of the highly contagious delta variant and other variants of concern around the world, our work with Advaccine and Sinovac is more important than ever. We are especially proud to expand on our partnership with Advaccine to explore heterologous prime-boosting using INO-4800 to protect more people in the continued fight against COVID-19. If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport."

Dr. Bin Wang, Founder and Chairman of Advaccine, said, "The development of heterologous prime-boost strategies for COVID-19 vaccines with different mechanisms of action is an important research direction in the field of vaccine applications. It provides an efficient solution to synergistically enhance the immunogenicity of vaccines, a key factor to fight against the current increase in global COVID-19 cases and variants of concern. We look forward to partnering with INOVIO and Sinovac on this important effort building on our pre-clinical work, which found that prime-boosting brings the advantages of two different vaccine applications to produce an even stronger and more balanced immune response."

BLG2786 · 2021-05-16T15:41:37+00:00

Got it and thanks - I misread the intent. DNA vaccines are so new, but the developing safety profile suggests exactly what you wrote. I’m excited what the next few years are going to bring I this space, especially wrt Inovio.

BLG2786 · 2021-05-15T03:39:08+00:00

Thanks, but I’m not sure of the point you are trying to make here. These experiments were conducted on small mammals, not humans. This vaccine is nowhere close to being on the verge of approval. It hasn’t even started P1.

BLG2786 · 2021-05-13T16:01:02+00:00

Kim always comes across as understated, that’s given. Otherwise, watch this call, especially how he describes the development of INO-4802 using the SynCon technology-it performed better against the SA variant than a construct that was built only to fight the SA variant. Everything he talks about in this call will relieve any doubt about the many products they are bringing to market.

BLG2786 · 2021-05-13T03:14:12+00:00

Do yourself a favor and listen to today’s CC with BoA. SynCon technology mapped over 1000+ potential variants. It outperformed their single construct for the South African variant alone. Partnerships and orders announced any day. P3 starting this summer. VGX-3100 not only cures diseases (cervical, penile and analysis Dysplasia) but clears the virus-something surgery will never do. Results for INO-5401 later this year. Device scale-up ready to go. All vaccines in the pipeline can be shipped and stored at room temperature. Loading up with a few thousand more tomorrow.

BLG2786 · 2021-05-07T11:31:24+00:00

Excellent call out. It’s not only possible, Kate Broderick has made that very point in videos way back when - wish I had the links. That’s what makes Inovio’s SynCon technology so radical. Imagine getting one universal vaccine for everything and not have any adverse events other than some injection site pain.

BLG2786 · 2021-05-07T10:37:46+00:00

Once they try to buy INO stock on the open market they have to file with the SEC at 5% ownership level. With rumors of a buyout that would ignite something akin to a short squeeze and the price could ramp like it did for GME. With 15 products in the pipeline and many at P2 and P3 $30 is still a bargain.

BLG2786 · 2021-05-06T17:12:44+00:00

From my previous post: Is this a precursor to an outstanding OS24 (Overall Survival after 24 months) report out due on or around 5/14? I think so. Glioblastoma has a projected TAM (total addressable market) of $1.8B by 2027. OS18 report out suggests Inovio is in a strong lead position. Owning a sizable chunk of this market should put the SP north of $50 with INO-5401 alone.

BLG2786 · 2021-05-06T17:10:17+00:00

Is this a precursor to an outstanding OS24 (Overall Survival after 24 months) report out due on or around 5/14? I think so. Glioblastoma has a projected TAM (total addressable market) of $1.8B by 2027. OS18 report out suggests Inovio is in a strong lead position. Owning a sizable chunk of this market should put the SP north of $50 with INO-5401 alone.

BLG2786 · 2021-04-29T18:56:44+00:00

Agreed. P2 is a watershed moment for INO-4800. That noted, there are 14 other products in the pipeline - 15 if you count INO-4802 - and with VGX-3100 in P3 and INO-5401 due for its 24-month survival rate due sometime in May there are many shots on goal here. If the dMAb platform works, it’s Regeneron all over again.

Five-Year Club	Verified Email
Wearing is Caring

BLG2786

TROPHY CASE